Bladder Cancer

FDA approves avelumab as frontline maintenance in urothelial carcinoma

July 01, 2020

The FDA has approved the PD-L1 inhibitor avelumab for the frontline maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma.

Personalized cancer vaccine combo induces clinical benefit in advanced solid tumors

June 22, 2020

The combination of the personalized cancer vaccine RO719845 and the PD-L1 inhibitor atezolizumab showed strong clinical activity across solid tumors, including bladder cancer and renal cell carcinoma.

Atezolizumab shows similar efficacy in upper tract urothelial carcinoma and standard bladder cancer

June 19, 2020

Median overall survival is the same for both malignancies, study results show.

Biomarker combo forecasts improved survival with anti–PD-1/L1 agents in bladder cancer

June 18, 2020

The dual biomarker of ARID1A mutations and CXCL13 expression was associated with improved overall survival in patients with advanced urothelial carcinoma.

Immune checkpoint inhibitors effective in variant urothelial carcinoma

June 17, 2020

Anti–PD-1/PD-L1 agents were associated with similar efficacy across pure and variant histologies in patients with advanced urothelial carcinoma, with the exception of those with a neuroendocrine variant.

FDA approves pembrolizumab across TMB-high solid tumors

June 17, 2020

Pembrolizumab has been granted a second tumor-agnostic FDA indication, this one for patients with solid tumors with a high tumor mutational burden.

Neoadjuvant pembrolizumab regimen impresses in locally advanced urothelial cancer

June 17, 2020

Neoadjuvant pembrolizumab plus chemotherapy achieved a high rate of pathologic downstaging to noninvasive disease and was associated with a high radical cystectomy rate in cisplatin-eligible patients with urothelial cancer.

Addition to avelumab to best supportive care after firstline chemo improves OS in advanced urothelial Ca

June 03, 2020

Avelumab (Bavencio) as a maintenance treatment after chemotherapy significantly extended overall survival in patients with advanced urothelial cancer, according to findings from thephase III JAVELIN Bladder 100 trial.

Is a reduced bacillus Calmette-Guérin regimen feasible?

June 02, 2020

"In the era of BCG shortage, it would have been highly desirable to demonstrate the efficacy and safety of fewer BCG instillations for high-risk bladder cancer. However, reduced frequency of maintenance BCG instillations is associated with increased risk of cancer recurrence, albeit with fewer adverse effects," writes Badar M. Mian, MD.

FDA approves additional recommended dosage for anti-PD-1 therapy

May 13, 2020

The FDA approved an additional recommended dosage of 400 mg every 6 weeks for the anti-PD-1 therapy pembrolizumab (Keytruda), across all adult indications, including monotherapy and combination therapy, Merck reported.